PAVmed Statistics
Total Valuation
PAVmed has a market cap or net worth of $22.01 million. The enterprise value is $51.58 million.
Important Dates
The next confirmed earnings date is Thursday, May 15, 2025, before market open.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PAVmed has 31.16 million shares outstanding. The number of shares has increased by 802.87% in one year.
| Current Share Class | 31.16M |
| Shares Outstanding | 31.16M |
| Shares Change (YoY) | +802.87% |
| Shares Change (QoQ) | +196.70% |
| Owned by Insiders (%) | 4.31% |
| Owned by Institutions (%) | 7.49% |
| Float | 27.25M |
Valuation Ratios
The trailing PE ratio is 1.42.
| PE Ratio | 1.42 |
| Forward PE | n/a |
| PS Ratio | 2.20 |
| Forward PS | 70.62 |
| PB Ratio | -3.02 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 1.61 |
| EV / Sales | 17.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.06
| Current Ratio | 0.06 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -988.60 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -87.19% |
| Return on Invested Capital (ROIC) | -112.26% |
| Return on Capital Employed (ROCE) | 929.52% |
| Revenue Per Employee | $76,795 |
| Profits Per Employee | $819,641 |
| Employee Count | 39 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 12.02 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.69% in the last 52 weeks. The beta is 1.12, so PAVmed's price volatility has been higher than the market average.
| Beta (5Y) | 1.12 |
| 52-Week Price Change | -66.69% |
| 50-Day Moving Average | 0.71 |
| 200-Day Moving Average | 0.88 |
| Relative Strength Index (RSI) | 47.98 |
| Average Volume (20 Days) | 81,903 |
Short Selling Information
The latest short interest is 233,297, so 0.75% of the outstanding shares have been sold short.
| Short Interest | 233,297 |
| Short Previous Month | 237,355 |
| Short % of Shares Out | 0.75% |
| Short % of Float | 0.86% |
| Short Ratio (days to cover) | 1.97 |
Income Statement
In the last 12 months, PAVmed had revenue of $3.00 million and earned $31.97 million in profits. Earnings per share was $0.50.
| Revenue | 3.00M |
| Gross Profit | -1.85M |
| Operating Income | -44.49M |
| Pretax Income | -61.46M |
| Net Income | 31.97M |
| EBITDA | -43.29M |
| EBIT | -44.49M |
| Earnings Per Share (EPS) | $0.50 |
Full Income StatementBalance Sheet
The company has $1.53 million in cash and $31.86 million in debt, giving a net cash position of -$30.33 million or -$0.97 per share.
| Cash & Cash Equivalents | 1.53M |
| Total Debt | 31.86M |
| Net Cash | -30.33M |
| Net Cash Per Share | -$0.97 |
| Equity (Book Value) | -7.03M |
| Book Value Per Share | -0.52 |
| Working Capital | -33.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$33.55 million and capital expenditures -$55,000, giving a free cash flow of -$33.61 million.
| Operating Cash Flow | -33.55M |
| Capital Expenditures | -55,000 |
| Free Cash Flow | -33.61M |
| FCF Per Share | -$1.08 |
Full Cash Flow StatementMargins
Gross margin is -61.60%, with operating and profit margins of -1,485.38% and 1,328.58%.
| Gross Margin | -61.60% |
| Operating Margin | -1,485.38% |
| Pretax Margin | 949.15% |
| Profit Margin | 1,328.58% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PAVmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -802.87% |
| Shareholder Yield | -802.87% |
| Earnings Yield | 150.43% |
| FCF Yield | -158.16% |
Dividend DetailsAnalyst Forecast
The average price target for PAVmed is $19.50, which is 2,661.26% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.50 |
| Price Target Difference | 2,661.26% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 153.17% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on December 7, 2023. It was a reverse split with a ratio of 0.0666667:1.
| Last Split Date | Dec 7, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.0666667:1 |
Scores
PAVmed has an Altman Z-Score of -17.41 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.41 |
| Piotroski F-Score | 3 |